Strategic Partnerships MTTI pursues collaborations with capital markets and industry partners as evidenced by partnerships with Brookline Capital Markets and engagement at industry summits, presenting a sales opportunity to offer radiopharmaceutical manufacturing, clinical development support, and regulatory advisory services.

Clinical Leadership Recent hires and appointments of CMO and SVP Clinical Development signal a focus on advancing clinical programs; leverage this to propose comprehensive clinical trial support, trial design consulting, and translational research services to accelerate DTP radiopharmaceutical programs.

Clinical Data Momentum Publicized clinical data on two-cycle EBTATE and enhanced tumor targeting in GEP-NET patients at SNMMI 2026 indicates growing value in radiopharmaceutical efficacy; opportunity to present analytics, imaging partnerships, and regulatory strategy assistance to expand program adoption.

Market Readiness As a small, focused life sciences entity with ongoing clinical development and international collaboration potential, position offerings around scalable research services, CRO/CMO-level support, and manufacturing supply chain optimization for targeted radionuclide therapies.

Funding and Visibility Active conference participation and press coverage, plus existing investor-facing events, create a channel for offering funding strategy, grant support, and partnerships to accelerate program milestones and de-risk early-stage radiopharmaceutical ventures.